Addus HomeCare Corporation

NasdaqGS:ADUS Stock Report

Market Cap: US$1.9b

Addus HomeCare Valuation

Is ADUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ADUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$210.24
Fair Value
50.2% undervalued intrinsic discount
10
Number of Analysts

Below Fair Value: ADUS ($104.8) is trading below our estimate of fair value ($210.24)

Significantly Below Fair Value: ADUS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ADUS?

Key metric: As ADUS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ADUS. This is calculated by dividing ADUS's market cap by their current earnings.
What is ADUS's PE Ratio?
PE Ratio25.9x
EarningsUS$73.60m
Market CapUS$1.87b

Price to Earnings Ratio vs Peers

How does ADUS's PE Ratio compare to its peers?

The above table shows the PE ratio for ADUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average79.1x
PINC Premier
47.3x29.6%US$1.9b
ASTH Astrana Health
36.3x26.7%US$1.6b
PRVA Privia Health Group
198x30.5%US$2.8b
AMED Amedisys
34.7x32.4%US$3.1b
ADUS Addus HomeCare
25.9x14.8%US$1.9b

Price-To-Earnings vs Peers: ADUS is good value based on its Price-To-Earnings Ratio (25.9x) compared to the peer average (79.1x).

Price to Earnings Ratio vs Industry

How does ADUS's PE Ratio compare vs other companies in the US Healthcare Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
IDXG Interpace Biosciences
0.5xn/aUS$2.78m
MDCE Medical Care Technologies
3.9xn/aUS$986.43k
CMAX.Q CareMax
n/a77.2%US$3.00
IONM Assure Holdings
n/an/aUS$3.00
No more companies available in this PE range
ADUS 25.9xIndustry Avg. 23.6xNo. of Companies10PE01632486480+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ADUS is expensive based on its Price-To-Earnings Ratio (25.9x) compared to the US Healthcare industry average (23.6x).

Price to Earnings Ratio vs Fair Ratio

What is ADUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ADUS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.9x
Fair PE Ratio22.1x

Price-To-Earnings vs Fair Ratio: ADUS is expensive based on its Price-To-Earnings Ratio (25.9x) compared to the estimated Fair Price-To-Earnings Ratio (22.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ADUS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$104.55
US$135.70
+29.8%
15.5%US$160.00US$83.00n/a10
Apr ’26US$98.93
US$136.27
+37.7%
14.7%US$160.00US$83.00n/a11
Mar ’26US$95.77
US$136.27
+42.3%
14.7%US$160.00US$83.00n/a11
Feb ’26US$125.16
US$139.00
+11.1%
13.3%US$153.00US$83.00n/a11
Jan ’26US$125.35
US$137.82
+9.9%
13.0%US$150.00US$83.00n/a11
Dec ’25US$122.84
US$136.60
+11.2%
13.4%US$150.00US$83.00n/a10
Nov ’25US$126.27
US$137.30
+8.7%
13.7%US$155.00US$83.00n/a10
Oct ’25US$128.72
US$134.00
+4.1%
13.6%US$145.00US$83.00n/a9
Sep ’25US$133.01
US$133.44
+0.3%
13.4%US$143.00US$83.00n/a9
Aug ’25US$121.95
US$123.71
+1.4%
13.7%US$136.00US$83.00n/a7
Jul ’25US$116.16
US$123.71
+6.5%
13.7%US$136.00US$83.00n/a7
Jun ’25US$114.81
US$117.00
+1.9%
12.6%US$129.00US$83.00n/a7
May ’25US$98.40
US$105.43
+7.1%
10.0%US$118.00US$83.00US$104.557
Apr ’25US$103.18
US$106.14
+2.9%
8.6%US$118.00US$88.00US$98.937
Mar ’25US$93.86
US$108.00
+15.1%
4.8%US$118.00US$102.00US$95.776
Feb ’25US$88.49
US$108.00
+22.0%
4.8%US$118.00US$102.00US$125.166
Jan ’25US$92.85
US$110.43
+18.9%
8.4%US$130.00US$102.00US$125.357
Dec ’24US$89.58
US$111.33
+24.3%
8.8%US$130.00US$102.00US$122.846
Nov ’24US$80.83
US$111.33
+37.7%
8.8%US$130.00US$102.00US$126.276
Oct ’24US$85.19
US$113.33
+33.0%
7.4%US$130.00US$105.00US$128.726
Sep ’24US$86.91
US$113.33
+30.4%
7.4%US$130.00US$105.00US$133.016
Aug ’24US$92.94
US$110.83
+19.3%
9.5%US$130.00US$100.00US$121.956
Jul ’24US$92.70
US$110.33
+19.0%
9.7%US$130.00US$100.00US$116.166
Jun ’24US$90.61
US$113.86
+25.7%
11.6%US$135.00US$100.00US$114.817
May ’24US$88.78
US$123.71
+39.3%
7.0%US$135.00US$105.00US$98.407
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
US$135.70
Fair Value
22.8% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/30 21:40
End of Day Share Price 2025/04/30 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Addus HomeCare Corporation is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian HoffmanAvondale Partners
Matthew GillmorBaird
Andrew MokBarclays